{"id":"strontium-89","safety":{"commonSideEffects":[{"rate":null,"effect":"Bone marrow suppression (thrombocytopenia, leukopenia)"},{"rate":null,"effect":"Transient increase in bone pain (flare reaction)"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1200625","moleculeType":"Small molecule","molecularWeight":"159.81"},"_dailymed":{"setId":"c89bcf16-399d-48e0-a4e3-849261aaa310","title":"STRONTIUM CHLORIDE SR-89 (STRONTIUM CHLORIDE SR-89) INJECTION [Q BIOMED INC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Strontium-89 mimics calcium and is preferentially taken up by osteoblasts in areas of high bone turnover, particularly metastatic bone lesions. Once localized, it emits beta particles that deliver high local radiation dose to the lesion while sparing surrounding normal bone tissue. This mechanism provides pain relief and may slow progression of bone metastases.","oneSentence":"Strontium-89 is a radioactive beta-emitting isotope that localizes to areas of increased bone metabolism and delivers targeted radiation to bone lesions.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:47:17.360Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic bone pain in patients with osteoblastic bone metastases (primarily prostate cancer and breast cancer)"}]},"trialDetails":[{"nctId":"NCT00365105","phase":"PHASE3","title":"Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2006-07-11","conditions":"Breast Cancer, Lung Cancer, Metastatic Cancer","enrollment":261},{"nctId":"NCT05466812","phase":"PHASE4","title":"Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2022-07-13","conditions":"Thyroid Neoplasm Follicular, Bone Metastases","enrollment":20},{"nctId":"NCT00080782","phase":"PHASE2","title":"Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2002-02","conditions":"Metastatic Cancer, Prostate Cancer","enrollment":14},{"nctId":"NCT00081159","phase":"PHASE2","title":"Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-07","conditions":"Metastatic Cancer, Prostate Cancer","enrollment":80},{"nctId":"NCT00024167","phase":"PHASE3","title":"Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2002-04","conditions":"Prostate Cancer","enrollment":265},{"nctId":"NCT00554918","phase":"PHASE2","title":"Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy","status":"COMPLETED","sponsor":"University Hospital Birmingham","startDate":"2005-02","conditions":"Metastatic Cancer, Prostate Cancer","enrollment":300},{"nctId":"NCT00002503","phase":"PHASE3","title":"Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1992-10","conditions":"Metastatic Cancer, Prostate Cancer","enrollment":204},{"nctId":"NCT00156884","phase":"PHASE2","title":"A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer","status":"COMPLETED","sponsor":"Alberta Health services","startDate":"2003-08","conditions":"Hormone Refractory Prostate Cancer, Bone Metastases","enrollment":58}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":362,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"strontium-89","genericName":"strontium-89","companyName":"Alberta Health services","companyId":"alberta-health-services","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Strontium-89 is a radioactive beta-emitting isotope that localizes to areas of increased bone metabolism and delivers targeted radiation to bone lesions. Used for Metastatic bone pain in patients with osteoblastic bone metastases (primarily prostate cancer and breast cancer).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}